用于实体瘤治疗的嵌合抗原受体修饰T细胞：明确挑战与后续步骤
Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.
作者信息
Beatty Gregory L, O'Hara Mark
机构信息
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Pharmacol Ther. 2016 Oct;166:30-9. doi: 10.1016/j.pharmthera.2016.06.010. Epub 2016 Jun 29.
Chimeric antigen receptor (CAR) T cell therapy has shown promise in CD19 expressing hematologic malignancies, but how to translate this success to solid malignancies remains elusive. Effective translation of CAR T cells to solid tumors will require an understanding of potential therapeutic barriers, including factors that regulate CAR T cells expansion, persistence, trafficking, and fate within tumors. Herein, we describe the current state of CAR T cells in solid tumors; define key barriers to CAR T cell efficacy and mechanisms underlying these barriers, outline potential avenues for overcoming these therapeutic obstacles, and discuss the future of translating CAR T cells for the treatment of patients with solid malignancies.
嵌合抗原受体（CAR）T细胞疗法在表达CD19的血液系统恶性肿瘤中已显示出前景，但如何将这一成功转化至实体恶性肿瘤仍不清楚。将CAR T细胞有效转化用于实体瘤将需要了解潜在的治疗障碍，包括调节CAR T细胞在肿瘤内的扩增、持久性、运输和命运的因素。在此，我们描述了实体瘤中CAR T细胞的现状；定义了CAR T细胞疗效的关键障碍以及这些障碍背后的机制，概述了克服这些治疗障碍的潜在途径，并讨论了将CAR T细胞转化用于治疗实体恶性肿瘤患者的未来。
Zotero 插件